ALX Oncology Holdings Inc.

ALXO Healthcare Biotechnology

In the quarter to June 2026, EPS grew 73.5%, free cash flow grew 31.7% and total debt fell 3.34%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.06 0.06 +6.00%
Market cap
$138.3M
P/E
0.0×
Fwd P/E
−8.6×
Dividend yield
—
F-score
n/a
Altman Z
154.45
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
9.71 7.21 2.07 2.40
Net Debt/EBITDA
7.05 6.96 1.52 2.24
Debt/Equity
0.07 0.06 0.38 0.23
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.12) (0.18) (0.35) (0.32)
Book value per Share
1.00 1.45 0.48 0.84
Free Cash Flow
(16.03) (18.70) (19.03) (17.15)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates